| Literature DB >> 28592282 |
Rocco Salvatore Calabrò1, Antonino Naro2, Margherita Russo2, Antonino Leo2, Rosaria De Luca2, Tina Balletta2, Antonio Buda2, Gianluca La Rosa2, Alessia Bramanti2, Placido Bramanti2.
Abstract
BACKGROUND: Many studies have demonstrated the usefulness of repetitive task practice by using robotic-assisted gait training (RAGT) devices, including Lokomat, for the treatment of lower limb paresis. Virtual reality (VR) has proved to be a valuable tool to improve neurorehabilitation training. The aim of our pilot randomized clinical trial was to understand the neurophysiological basis of motor function recovery induced by the association between RAGT (by using Lokomat device) and VR (an animated avatar in a 2D VR) by studying electroencephalographic (EEG) oscillations.Entities:
Keywords: Ersp; Lokomat; Loreta; Mirror neuron system; Virtual reality
Mesh:
Year: 2017 PMID: 28592282 PMCID: PMC5463350 DOI: 10.1186/s12984-017-0268-4
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Shows the individual clinical-demographic characteristics. There were no significant between-group differences in any parameter
| group | age | gender | lesion location | stroke onset | comorbidities |
|---|---|---|---|---|---|
| RAGT + VR | 68 | M | r FP | 12 | 3 |
| 63 | M | l PO | 7 | 2,3 | |
| 57 | M | r TP | 5 | 1,4 | |
| 62 | F | l PO | 7 | 1 | |
| 60 | M | r FP | 6 | 1,2 | |
| 59 | M | r P | 10 | 2,3 | |
| 66 | M | l F | 6 | 3 | |
| 56 | F | r FP | 10 | 1,2 | |
| 58 | M | l PO | 8 | 1,2,4 | |
| 55 | F | r FP | 8 | 1,4 | |
| 65 | F | l PO | 8 | 1,3 | |
| 55 | F | r TP | 7 | 1,4 | |
| mean ± SD | 60 ± 4 | 7 M;5F | 8 ± 2 | ||
| RAGT-VR | 58 | M | r P | 8 | 1,3,5 |
| 72 | F | l F | 11 | 2,3 | |
| 59 | M | l F | 5 | 1,2 | |
| 54 | M | r P | 5 | 2 | |
| 55 | F | r P | 10 | 1 | |
| 73 | M | r TP | 8 | 3,5 | |
| 63 | F | l TP | 8 | 2,2 | |
| 64 | M | r P | 11 | 2,3 | |
| 64 | F | l F | 6 | 3 | |
| 65 | M | r P | 8 | 1,3,5 | |
| 65 | F | l F | 8 | 2,3 | |
| 66 | M | l F | 8 | 3 | |
| mean ± SD | 63 ± 6 | 7 M;5F | 8 ± 2 |
Legend: F frontal; P parietal; O occipital; T temporal; l left; r right; 1 high blood pressure; 2 diabetes mellitus; 3 hypercholesterolemia; 4 smoking; 5 alcoholism
Fig. 1The virtual mirror (left), a sequence of the visual feedback (central), and combined visual-haptic modality (right)
Fig. 2The CONSORT flow diagram
Mean values (±SD) of clinical outcomes measure after RAGT ± VR. Within- and between-group comparisons, with confidence interval (95%) (CI), are reported. Not reported data are non-significant
|
| G | PRE | POST | W | B | CI (95%) |
|---|---|---|---|---|---|---|
| RMI | RAGT + VR | 8 ± 1 | 14 ± 1 | <0.001 | 0.001 | 1.2 |
| RAGT-VR | 7 ± 1 | 9 ± 1 | 0.01 | |||
| POMA | RAGT + VR | 17 ± 3 | 23 ± 3 | 0.001 | 0.01 | 1.2 |
| RAGT-VR | 12 ± 4 | 15 ± 4 | ||||
| MAS | RAGT + VR | 2 ± 0.5 | 2 ± 0.5 | |||
| RAGT-VR | 2 ± 0.5 | 2 ± 0.5 | ||||
| HRS | RAGT + VR | 11 ± 3 | 7 ± 3 | 0.01 | ||
| RAGT-VR | 13 ± 3 | 10 ± 3 | 0.02 | |||
| VAS | RAGT + VR | 6 ± 1 | 8 ± 1 | <0.001 | 0.01 | 1.3 |
| RAGT-VR | 5 ± 1 | 6 ± 1 | ||||
|
| RAGT + VR | 5 ± 1 | 2 ± 1 | <0.001 | 0.009 | 1 |
| RAGT-VR | 5 ± 1 | 5 ± 1 | ||||
| H | RAGT + VR | 36 ± 7 | 42 ± 3 | 0.01 | 0.02 | −6.2 |
| RAGT-VR | 34 ± 6 | 38 ± 10 | ||||
| K | RAGT + VR | 31 ± 8 | 47 ± 6 | <0.001 | 0.02 | |
| RAGT-VR | 30 ± 7 | 36 ± 3 | 0.04 |
Legend: RMI Rivermead Mobility Index; POMA Tinetti Performance Oriented Mobility Assessment; MAS Modified Ashwort Scale; HRS Hamilton Rating Scale for depression; VAS visual analogic scale
Fig. 3TPRE-TPOST changes in area activation during the entire gait cycle (panel a) or each phase of gait cycle (S1, T1, S2, and T2) (panel b) as identified by LORETA in RAGT + VR (a) and RAGT-VR (b) groups. Lesioned area is plotted on the left hemisphere. The colors refer to the voxel-by-voxel t-tests values for TPRE-TPOST changes (see Table 3)
Significant different LORETA activation (ANOVA F and p values) during gait cycle at TPOST as compared to TPRE (post-hoc p-value). Not reported data are non-significant
|
| RAGT + VR | RAGT-VR | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| TPRE-TPOST differences related to gait cycle phases |
| TPRE-TPOST differences related to gait cycle phases | |||||||||
| S1 | T1 | S2 | T2 | S1 | T1 | S2 | T2 | |||||
| 21, <0.001 | 28, <0.001 | C | <0.001 | <0.001 | 0.03 | <0.001 | 8, 0.01 | C | <0.001 | <0.001 | <0.001 | <0.001 |
| F | <0.001 | <0.001 | <0.001 | <0.001 | F | <0.001 | <0.001 | <0.001 | <0.001 | |||
| PO | 0.004 | 0.005 | <0.001 | <0.001 | PO | <0.001 | ||||||
Legend: t time, g group, e electrode, C central, F frontal, PO parieto-occipital; S1 first stationary phase; S2 second stationary phase; T1 first transition phases; T2 second transition phase
Summarizes the ANOVA findings concerning PRE-POST group differences of ERSP (F, p) (top) and the post-hoc p-values (t, p) (bottom) related to each phase of gait cycle. Not reported data are non-significant
| band |
| RAGT + VR | RAGT-VR | |||||
|---|---|---|---|---|---|---|---|---|
|
| C | F |
| C | F | |||
| μ | 8.6, <0.001 | 77, <0.001 | 71, <0.001 | 50, <0.001 | 16, <0.001 | 3, 0.007 | 5, <0.001 | |
| β | 15, <0.001 | 72, <0.001 | 87, <0.001 | 55, <0.001 | 39, <0.001 | 8, <0.001 | 9, <0.001 | |
| Lγ | 9.2, <0.001 | 66, <0.001 | 53, <0.001 | 12, <0.001 | 25, <0.001 | |||
| Hγ | 28, <0.001 | 37, <0.001 | 12, <0.001 | |||||
| ϑ | 8.9, <0.001 | 57, <0.001 | 51, <0.001 | 10, <0.001 | 18, <0.001 | |||
| band | electrode | group | PRE-POST differences related to gait cycle phases | |||||
| S1 | T1 | S2 | T2 | |||||
| μ | C | RAGT + VR | 3.3, 0.01 | −14, <0.001 | 3.4, 0.01 | |||
| RAGT-VR | 2.4, 0.04 | −6.3, 0.001 | 3.3, 0.01 | |||||
| F | RAGT + VR | 5, 0.002 | 4.5, 0.004 | |||||
| RAGT-VR | 3.6, 0.01 | 2.7, 0.03 | ||||||
| PO | RAGT + VR | -3.4, 0.01 | −5, 0.002 | −3.4, 0.01 | −3.6, 0.01 | |||
| RAGT-VR | -3.3, 0.01 | 4.5, 0.002 | −3.3, 0.01 | −2.7, 0.03 | ||||
| β | C | RAGT + VR | -26, <0.001 | 6, 0.001 | 4.8, 0.003 | |||
| RAGT-VR | -2.9, 0.02 | 3.9, 0.007 | 2.9, 0.02 | |||||
| F | RAGT + VR | -24, <0.001 | 8.3, <0.001 | 5.3, 0.002 | ||||
| RAGT-VR | -3.5, 0.01 | 3.5, 0.02 | 3.5, 0.01 | |||||
| ϑ | C | RAGT + VR | 5.1, 0.002 | |||||
| RAGT-VR | 3, 0.02 | |||||||
| Hγ | F | RAGT + VR | -3.5, 0.01 | −2.6, 0.03 | −5.2, 0.002 | |||
| RAGT-VR | ||||||||
| PO | RAGT + VR | -2.8, 0.02 | −4.4, 0.004 | −7, <0.001 | −4.5, 0.003 | |||
| RAGT-VR | ||||||||
| Lγ | C | RAGT + VR | 6, 0.001 | 5.1, 0.002 | ||||
| RAGT-VR | 3.5, 0.02 | 3.8, 0.008 | ||||||
| F | RAGT + VR | 15, <0.001 | 13, <0.001 | |||||
| RAGT-VR | 4.9, 0.003 | 4.9, 0.003 | ||||||
Legend: t time, g group, e electrode, C central, F frontal, PO parieto-occipital; S1 first stationary phase; S2 second stationary phase; T1 first transition phases; T2 second transition phase
Fig. 4Average TPRE-TPOST changes in gait event-related spectral perturbation (ERSPs) in RAGT + VR (a) and RAGT-VR (b) groups. Non-significant differences relative to the full gait cycle baseline (p ≤ 0.05) are masked in green (see Table 4)
Summarizes the significant PRE-POST differences (t, p) of scalp projections. Not reported data are non-significant
| band | RAGT + VR | RAGT-VR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| C | F | PO | C | F | PO | ||||
| μ -ERD | 5 < 0.001 | 11, <0.001 | 6, <0.001 | 4, <0.001 | |||||
| β -ERD | 10, <0.001 | 4, <0.001 | 6, <0.001 | 6, <0.001 | 3, <0.001 | ||||
| μ -ERS | 5, <0.001 | 8, <0.001 | 13, <0.001 | 10, <0.001 | |||||
| β -ERS | 4, <0.001 | 13, <0.001 | |||||||
| ϑ -ERS | 5, <0.001 | 4, <0.001 | 6, <0.001 | 4, <0.001 | |||||
| Lγ -ERS | 7, <0.001 | 4, <0.001 | 6, <0.001 | 22, <0.001 | |||||
| Hγ -ERD | 4, <0.001 | 4, <0.001 | |||||||
Legend: t time, g group, e electrode, C central, F frontal, PO parieto-occipital
Fig. 5Average changes at TPOST as compared to TPRE in scalp ERP projections relatively to the full gait cycle. The left and right hemispheres plots correspond to the affected and unaffected ones, respectively. ERS and ERD are masked in red and blue tones, respectively, whereas non-significant differences are in green (see Table 5)